脓毒症的分子表型与液体复苏的差异反应
本研究基于CLOVERS临床试验入组时采集血浆的1289例脓毒症患者,用包含血管生成素-1、血管生成素-2和可溶性肿瘤坏死因子受体-1的简约预测模型将其分为SP1(1016例)和SP2(273例)两个分子亚表型。SP2以更严重的内皮损伤和炎症为特征,其不良临床结局风险高于SP1,且独立于人口学、合并症和疾病严重程度评分。SP2患者接受宽松液体策略较限制性策略28天死亡率更高(41% vs 27%),SP1患者则无差异(9% vs 9%)(交互作用P=0.02);SP2接受宽松策略时无通气、无肾脏替代治疗和无血管加压药天数更少。作者认为,未来前瞻性识别这些亚表型可能为脓毒症的精准导向治疗提供依据。
要点
- 在CLOVERS试验的1289例脓毒症患者中,用血管生成素-1、血管生成素-2和可溶性肿瘤坏死因子受体-1的简约模型可分出SP1(1016例)和SP2(273例)两个亚表型。
- SP2以更严重的内皮损伤和炎症为特征,其不良临床结局风险高于SP1,且独立于人口学、合并症和疾病严重程度评分。
- SP2患者宽松液体策略较限制性策略28天死亡率更高(41% vs 27%),SP1患者无差异(9% vs 9%),交互作用P=0.02。
- SP2患者接受宽松较限制性复苏策略时,无通气、无肾脏替代治疗和无血管加压药天数更少。
- 作者认为未来前瞻性识别这些亚表型可能为脓毒症的精准导向治疗提供依据。
适用人群与场景
- 纳入CLOVERS临床试验且研究入组时采集了血浆的脓毒症患者,共1289例。
诊断标准与关键阈值
- 使用既往验证的简约预测模型,包含血管生成素-1、血管生成素-2和可溶性肿瘤坏死因子受体-1,将患者分为SP1和SP2两个亚表型。
研究设计与关键结果
- 研究类型为基于CLOVERS临床试验的亚组分析,样本量1289例,识别出SP1 1016例和SP2 273例。
- SP2以更严重的内皮损伤和炎症为特征,其不良临床结局风险高于SP1,独立于人口学、合并症和疾病严重程度评分。
- SP2患者宽松液体策略较限制性策略28天死亡率更高(41% vs 27%),SP1患者无差异(9% vs 9%),交互作用P=0.02。
- SP2患者接受宽松较限制性复苏策略时,无通气、无肾脏替代治疗和无血管加压药天数更少。
证据类型、等级与局限
- 证据类型为基于随机对照试验CLOVERS的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,未来前瞻性识别这些亚表型可能为脓毒症的精准导向治疗提供依据。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: Biological heterogeneity in critical illness syndromes, such as sepsis and acute kidney injury (AKI), has hindered development of effective therapies. In sepsis-associated AKI, two molecular subphenotypes (SP1 and SP2) have been identified with differing characteristics, outcomes, and response to vasopressor treatment. It is unknown if these subphenotypes extend to all patients with sepsis and whether they respond differently to fluid resuscitation strategy. Methods: Patients enrolled in the CLOVERS clinical trial with plasma collected at study enrollment were classified into two subphenotypes using a previously validated parsimonious prediction model that included angiopoietin-1 and -2 and soluble tumor necrosis factor receptor-1. Kaplan-Meier estimates were used to test differences in outcomes and subphenotype by treatment interaction. Measurements and Main Results: Among 1,289 patients, we identified 1,016 as SP1 and 273 as SP2. The risk of poor clinical outcomes was greater in SP2 than in SP1 independent of demographics, comorbidities, and illness severity scores. Patients with SP2, characterized by more severe endothelial injury and inflammation, had higher 28-day mortality with a liberal versus restrictive fluid strategy (41% vs. 27%), whereas patients with SP1 had no difference (9% vs. 9%) (P value for interaction = 0.02). Furthermore, SP2 had fewer days free from ventilation, renal replacement therapy, and vasopressors with a liberal compared with a restrictive resuscitation strategy. Conclusions: Molecular subphenotypes previously identified in AKI are also identifiable in sepsis and respond differently to fluid resuscitation strategy. Future prospective identification of these subphenotypes could inform a precision-guided therapeutic approach in sepsis.
参考来源
- Kiernan E, Zelnick LR, Khader A, et al. Molecular Phenotyping of Sepsis and Differential Response to Fluid Resuscitation. Am J Respir Crit Care Med. 2025. PMID: 40668865. doi:10.1164/rccm.202412-2377OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。